Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis

Br J Haematol. 2018 Nov;183(4):678-681. doi: 10.1111/bjh.15010. Epub 2017 Nov 23.

Authors

Ayalew Tefferi¹, Terra L Lasho¹, Curtis A Hanson², Rhett P Ketterling³, Naseema Gangat¹, Animesh Pardanani¹

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
³ Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.

PMID: 29171022
DOI: 10.1111/bjh.15010

No abstract available

Keywords: allogeneic; primary myelofibrosis; prognosis; survival; transplant.

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Clinical Decision-Making*
Disease-Free Survival
Female
Follow-Up Studies
Genetic Testing*
Humans
Male
Middle Aged
Mutation*
Primary Myelofibrosis / genetics*
Primary Myelofibrosis / mortality*
Primary Myelofibrosis / therapy
Repressor Proteins / genetics*
Serine-Arginine Splicing Factors / genetics*
Survival Rate

Substances

ASXL1 protein, human
Repressor Proteins
SRSF2 protein, human
Serine-Arginine Splicing Factors